Thrombolytics save $3,000/patient v. primary angioplasty -- NEJM study.
Executive Summary
THROMBOLYTICS SAVE $3,000/PATIENT v. PRIMARY ANGIOPLASTY while demonstrating a similar mortality rate, according to a retrospective cohort study published in the Oct. 24 New England Journal of Medicine. "We observed no benefits in terms of either mortality or the use of resources with a strategy of primary angioplasty rather than thrombolytic therapy," Nathan Every, MD, University of Washington, et al. state.